Evaluation of Teriparatide for Treatment of Osteoporosis in Four Patients with Cystic Fibrosis: A Case Series
Author(s) -
Oranan Siwamogsatham,
Kelly Stephens,
Vin Tangpricha
Publication year - 2014
Publication title -
case reports in endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.26
H-Index - 6
eISSN - 2090-6501
pISSN - 2090-651X
DOI - 10.1155/2014/893589
Subject(s) - teriparatide , medicine , osteoporosis , cystic fibrosis , bone mineral , disease , surgery , bone disease , complication , pediatrics
. Bone disease is a common complication of cystic fibrosis (CF). To date, there have been no reports on the effectiveness of teriparatide, recombinant human parathyroid hormone, to treat CF-related bone disease. Case Presentation. We report on four patients with CF-related bone disease who were treated with teriparatide. Three patients completed two years of therapy with teriparatide, and all had significant improvements in their bone mineral density (BMD). One patient was unable to tolerate teriparatide and discontinued treatment 1 week into therapy. Conclusion. Teriparatide may be a potential treatment option for CF-related bone disease. This report highlights the need for further investigation into the use of teripartide in the CF population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom